| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | 0.0078 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.9 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.0072 | 0.9 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |